DYRK1A and non-small cell lung carcinoma: Those patients with NSCLC can achieve little benefit from EGFR‐TKIs therapy.38 Thus, DYRK1A inhibition plus AZD9291 may be effective to treat EGFR wild‐type NSCLC patients.